Ted Lamson, co-founder and CTO of NeoTract, shares his philosophy on the evidence requirements for a quality-of-life solution like the NeoTract offering.

Ted Lamson, co-founder and CTO of NeoTract, describes his approach to proving the feasibility of the company’s solution in humans before making a more substantial investment in development and testing.

Ted Lamson, co-founder and CTO of NeoTract, outlines some of the key factors NeoTract considered in setting up its first-in-human study.

Ted Lamson, co-founder and CTO of NeoTract, comments on how it can sometimes be beneficial to conduct early clinical work outside the U.S.

Ted Lamson, co-founder and CTO of NeoTract, shares his experience and some pointer on clinical study design and devising a publication strategy.

Ted Lamson, co-founder and CTO of NeoTract, explains why and when NeoTract decided to pursue a CE Mark.

Ted Lamson, co-founder and CTO of NeoTract, describes how his company’s pursued a CE Mark.

Ted Lamson, co-founder and CTO of NeoTract, shares how and why his company undertook as selective European launch after receiving its CE Mark.

Ted Lamson, co-founder and CTO of NeoTract, explains when his company was approached by NICE and how it managed those interactions.

Ted Lamson, co-founder and CTO of NeoTract, discusses his technology’s initial NICE decision and the effect it has had on the company.

Ted Lamson, co-founder and CTO of NeoTract, comments on pricing for medtech products.